Vutrisiran
AssetAlso ALN-65492, ALN-TTRSC02, ALN-TTRSC02 FREE ACID
Silences hepatic TTR messenger RNA, reducing transthyretin production and subsequent amyloid deposition.
- Stage
- Phase 3
- Modality
- Oligonucleotide
- Target
- Proteostasis
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Transthyretin amyloidosis (attr) with cardiomyopathy
Phase 3, Active not recruiting, NCT04153149, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors6
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.